Michał Michalczyk

Michał Michalczyk

Auto-generated profile, based on publicly available information

Michał Michalczyk

Department of Gynecology and Obstetrics, Collegium Medicum, University of Zielona Góra, 65-417Zielona Góra, Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAleksander Celewicz
Aleksander Celewicz
MCMarta Celewicz
Marta Celewicz
MMMichał Michalczyk
Michał Michalczyk
PWPaula Woźniakowska-Gondek
Paula Woźniakowska-Gondek
KKKamila Krejczy
Kamila Krejczy
RRRafał Rzepka
Rafał Rzepka
Since first being identified in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an etiological agent behind Coronavirus disease 19 (COVID-19), has caused three waves of a global pandemic, with a fourth in progress. Despite its high percentage of asymptomatic and low-symptomatic courses of illness, the SARS-CoV-2 pandemic has claimed a higher death toll than the SARS-CoV and MERS-CoV epidemics because of its high infectivity when compared to the other coronaviruses. High COVID-19 mortality is associated with age and other coexisting morbidities, as well as healthcare quality. According to several studies, pregnant women are at a higher risk of severe COVID-19 infection and adverse pregnancy outcomes (caesarean delivery, pre-term birth, low birth weight, preeclampsia, ICU admission, and need for mechanical ventilation). In our review of recent literature, we focused on the effects of COVID-19 in pregnant women, emphasizing the subcellular pathophysiology of SARS-CoV-2. In this paper, we concentrate on the pathophysiology of sub-cellular changes in COVID-19 and endeavor to highlight the aspects that manifest in physiological pregnancy and potentially create a higher risk of SARS-CoV-2 infection and acute COVID-19 symptoms. Understanding how pregnancy-associated changes can cause a synergistic effect with COVID-19 may point us in the right direction for future prophylaxis and treatment for women undergoing COVID-19 during pregnancy.

19 April 2023 in Annals of Medicine
Verified
Journal Article
Open access
ACAleksander Celewicz
Aleksander Celewicz
MCMarta Celewicz
Marta Celewicz
MMMichał Michalczyk
Michał Michalczyk
PWPaula Woźniakowska-Gondek
Paula Woźniakowska-Gondek
KKKamila Krejczy
Kamila Krejczy
RRRafał Rzepka
Rafał Rzepka
Since SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was first identified as the cause of Coronavirus disease 19 (COVID-19) it has caused over 649,147,421 infections and over 6,730,38...

25 March 2020 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
ACAleksander Celewicz
Aleksander Celewicz
MCMarta Celewicz
Marta Celewicz
MMMichał Michalczyk
Michał Michalczyk
RRRafał Rzepka
Rafał Rzepka
As cervical cancer is one of the most common malignancies in women worldwide even with present screening methods, the incidence in most developed countries is not decreasing for the last 15-20 years. A shift has been observed in the age of diagnosis in favour of younger women, and treatment of already developed cervical cancer is a challenge for surgeons. It is imperative to find new diagnostic methods for accurately pointing out patients at high risk of developing malignant disease and developing personalized treatment. Since cervical cancer is almost exclusively associated with HPV infection, understanding changes happening in an infected cell may prove invaluable for search of such methods, but it may also prove helpful in the diagnosis and treatment of other anogenital and nasopharyngeal region cancers. This review follows HPV-related changes in infected cell biology to point what potential markers and targets for therapy are in option when dealing with HPV-related diseases.